Kalaris Therapeutics Inc. (NASDAQ:KLRS) Stock Has Consensus Price Target of $18.75 According to Analysts

Shares of Kalaris Therapeutics Inc. (NASDAQ:KLRS) have received a consensus recommendation of “Moderate Buy” from the seven brokerages that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating and six have given a buy rating to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $18.75.

KLRS has been the topic of a number of research analyst reports. Wall Street Zen downgraded Kalaris Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, September 13th. Weiss Ratings raised Kalaris Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, September 24th. Finally, TD Cowen started coverage on Kalaris Therapeutics in a research report on Monday, June 15th. They set a “buy” rating for the company.

Kalaris Therapeutics Price Performance

KLRS stock opened at $2.85 on Friday. The firm has a market capitalization of $67.86 million, a P/E ratio of -1.41 and a beta of 0.42. Kalaris Therapeutics has a 52-week low of $2.75 and a 52-week high of $11.88. The company’s 50 day simple moving average is $3.66 and its 200-day simple moving average is $4.68.

Kalaris Therapeutics (NASDAQ:KLRS) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.48) EPS for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.02. Sell-side analysts predict that Kalaris Therapeutics will post -1.99 EPS for the current fiscal year.

Institutional Trading of Kalaris Therapeutics

A number of hedge funds have recently made changes to their positions in KLRS. ADAR1 Capital Management LLC purchased a new stake in shares of Kalaris Therapeutics during the second quarter worth $407,000. Simplify Asset Management Inc. increased its position in Kalaris Therapeutics by 335.5% in the 1st quarter. Simplify Asset Management Inc. now owns 87,426 shares of the company’s stock worth $504,000 after purchasing an additional 67,352 shares during the last quarter. BlackRock Inc. purchased a new stake in shares of Kalaris Therapeutics during the 2nd quarter worth about $222,000. Propel Bio Management LLC purchased a new stake in shares of Kalaris Therapeutics during the 4th quarter worth about $355,000. Finally, Pale Fire Capital SE bought a new stake in shares of Kalaris Therapeutics in the 2nd quarter valued at approximately $161,000. 66.05% of the stock is owned by hedge funds and other institutional investors.

About Kalaris Therapeutics

Kalaris Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for retinal vascular diseases and other serious eye disorders. Its research programs are aimed at addressing diseases in which abnormal blood-vessel growth or leakage can impair vision.

The company’s activities include the discovery and clinical development of investigational ophthalmic medicines intended to improve outcomes for patients with retinal conditions. Kalaris Therapeutics has not yet established a broad portfolio of marketed products, and its principal programs remain in development.

Publicly available information about the company’s broader operating history, geographic reach and leadership is limited.